WO2005054472A1 - 細胞膨張化致死毒およびそれを標的としたカンピロバクター属に属する細菌の検出 - Google Patents
細胞膨張化致死毒およびそれを標的としたカンピロバクター属に属する細菌の検出 Download PDFInfo
- Publication number
- WO2005054472A1 WO2005054472A1 PCT/JP2004/018042 JP2004018042W WO2005054472A1 WO 2005054472 A1 WO2005054472 A1 WO 2005054472A1 JP 2004018042 W JP2004018042 W JP 2004018042W WO 2005054472 A1 WO2005054472 A1 WO 2005054472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- primer pair
- genomic dna
- campylobacter
- seq
- primer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6879—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a cell swelling toxin of Campylobacter i. Coli and a polynucleotide encoding the same.
- the present invention is directed to the presence or absence of Campylobacter spp. In specimens (clinical specimens, foods, etc.) targeting the cell swelling lethal toxin of Campylobacter spp. A method for determining.
- Campylobacter bacteria are pathogens of humans and wild or domestic animals, and are causative of abortion and enteritis in animals and enteritis in humans.
- Campylobacter infection is known to be Campylobacter jejuni (Campylobacter jejuni) and Campylobacter coli (Campylobacter coli), and these bacteria are designated as food poisoning bacteria.
- Campylobacter jejuni Campylobacter jejuni
- Campylobacter coli Campylobacter coli
- Campylobacter was classified into 15 bacterial species and 9 subspecies. Among the bacterial species isolated from human diarrhea, C. jejuii accounted for 95-99%, and C. coli And other bacterial species are several percent (see Non-Patent Document 3). C. coli has a very high colonization rate in pigs. In recent years, Campylobacter infectious diseases have been increasing due to the increase in imported meat, especially in Southeast Asia.In particular, chicken-related foods, whose consumption has been increasing as a substitute for beef due to problems such as BSE and 0-157, have increased. The number of cases of infection is increasing rapidly.
- C. fetus (Campylobacter fetus) was known as an abortion bacterium of sheep and locusts, but has recently been reported to be involved in human abortion and premature birth.
- C. fetus infections caused by live cattle-contaminated liver and beef may cause symptoms such as sepsis and meningitis.
- the most important source of human infection is chicken, which carries a high concentration in the intestinal tract.
- Campylobacter Bacteria belonging to the genus Campylobacter are usually found in the digestive tract of animals such as horses, sheep, pigs, and birds. It is distributed at a high rate and is recognized as a bacterium causing zoonotic diseases. Campylobacter Infectious diseases are most likely caused by chickens.Infections are caused by direct contact with these animals or excreta, or by ingestion or cooking of food, drinking water, milk, etc. contaminated by the excreta. I do. In addition, cases of infection in facilities such as neonatal rooms have been reported (see Non-Patent Document 5).
- Campylobacter infections can cause gastrointestinal symptoms such as diarrhea with an incubation period of 3-7 days (sometimes bloody mucosal diarrhea), abdominal pain, fever, nausea, vomiting, headache, chills, and malaise Is a feature. Although less lethal, neonates can develop systemic infections such as sepsis and meningitis. In many cases, recovery can take from a few days to about a week, and the general prognosis is good except for some immunodeficient patients. However, in recent years, cases have been reported that progress to Guillain-Barré syndrome and Fisher syndrome, which are autoimmune diseases as post-infectious diseases of Campylobacter. Cases subsequent to Campylobacter infection are generally more severe, and the remission rate one year after onset is only about 60%.
- Campylobacter is a microaerobic bacterium.
- a special medium such as a skilow medium and a special device for maintaining the oxygen concentration at an absolute microaerobic condition of 3 to 10% (such as an anaerobic jar) are used.
- Campylobacter bacteria must be tested within 2-3 hours after they are killed in the air or collected immediately.
- Campylobacter infections have a long incubation period (3-7 days), their pathology often appears and bacteria cannot be isolated even if bacteria are identified in the food involved.
- Campylobacter bacteria it has been reported that infection can be established with a few hundred bacteria that are extremely infectious, and it is extremely difficult to identify the source of infection.
- a method for examining the hydrolysis of hippurate is one of the differential diagnoses of C. jeju and C. coli.
- C. jeju uses the ability to hydrolyze hippuric acid and the property that C. coli cannot. Again, this method is not feasible due to the presence of hippuric acid-negative C. jeju strain (see Non-Patent Document 6). Therefore, it is now possible to estimate the presence of Campylobacter bacteria based on feeding history and symptoms, and to examine the morphological and biological characteristics of the bacteria over several days in colonies that also had stool culture power. It is currently confirming its existence.
- Non-Patent Documents 9 and 10 Cytolethal Distending Toxin (CDT) has been discovered as a toxic factor from Kojuji (Non-Patent Document 11), and its relevance to pathogenicity has been attracting attention.
- CDT Cytolethal Distending Toxin
- Non-Patent Document 11 Cytolethal Distending Toxin
- Diarrheagenicity has been reported in an animal administration model using recombinant Escherichia coli that produces CDT of Shigella dysenteriae (Non-patent Document 12).
- CDT is a holotoxin consisting of three subunits called cdtA, cdtB and cdtC, and is encoded by genes arranged in tandem.
- the center of toxin activity is the type I deoxyribonuclease-like activity of the cdtB subunit, and the cdtA and cdtC subunits are thought to be involved in adhesion to target cells.
- the holotoxin acts on the cells, the cells swell, that is, swell to a large extent, and eventually the cells are killed.
- the molecular mechanism is that the cdtB subunit, which is the center of the active toxin, translocates to the nucleus in the cell, inserts a nick into chromosomal DNA by the type I deoxyribonuclease activity, and responds to DNA-damage response. cause. Then, it is thought that the cells are swelled and lethal after stopping the cell cycle at the G2 / M phase in order to activate the gene repair system (Non-patent Document 13). Furthermore, it has been confirmed that CDT acts on a wide range of cells such as epithelial cells and immunocompetent cells, and in particular, it is thought that it acts on human lymphocytes and causes apoptosis to escape from immunity. (Non-Patent Document 14).
- CDT has a unique molecular mechanism that is not found in conventional toxins. Until now, the entire base sequence of CDT in Campylobacter has become apparent. C. Jeju-only (Non-Patent Document 11).
- Patent Document 1 JP-A-62-228096
- Patent Document 2 JP-A-2-84200
- Patent Document 3 JP-A-2-154700
- Patent Document 4 JP-A-3-112498
- Patent Document 5 JP-A-6-90795
- Patent Document 6 JP-A-6-90796
- Patent Document 7 JP-A-2000-316590
- Non-patent Document l Blaser, et al, Ann.Intern. Med., 91: 179 (1979)
- Non-Patent Document 2 Tauxe, R., American Society for Microbiology, Washington DC.pg. 9 (1992)
- Non-Patent Document 3 Takahashi, M. et al, Infectious Diseases Weekly Report Japan, 3 (6): 10 (2001)
- Non-Patent Document 4 Simon, MS et al., 2003.Campylobacter infection.
- Non-Patent Document 5 Pediatrics, 29: 1219-1222 (1997)
- Non-Patent Document 6 Totten, et al, J. Clin.Microbiol, 25: 1747 (1987)
- Non-Patent Document 7 Romaniuk, P.J. et al, J. BacterioL, 169: 2173 (1987)
- Non-Patent Document 8 Oyofo, et al, J. Clin.Microbiol, 30: 2613 (1992)
- Non-Patent Document 9 Mizuno, K. et al, Microbios., 78: 215 (1994)
- Non-Patent Document 10 Suzuki, S. et al, FEMS Immunol. Med.MicribioL, 8: 207 (1994)
- Non-Patent Document 11 Pickett, C. et al. Infect. Immun., 64: 2070 (1996)
- Non-Patent Document 12 Infect.Immun., 65: 428-433 (1997)
- Non-Patent Document 13 Science, 290: 354-357 (2000)
- Non-Patent Document 14 J. Biol. Chem., 276: 5296-5302 (2001)
- the present invention provides a CDP of Campylobacter 1 'coli belonging to the genus Campylobacter, which allows rapid detection of Campylobacter bacteria by genetic diagnosis, and whose base sequence of the CDT has not yet been elucidated. It is an object of the present invention to provide a polynucleotide encoding Another object of the present invention is to provide Campylobacter 1. fetus CDT whose polynucleotide sequence has not been elucidated and a polynucleotide encoding the same.
- the present invention provides a CDT of a Campylobacter bacterium containing Campylobacter-1′-coli and Campylobacter-1′-phytas based on the knowledge obtained from the base sequence of Campylobacter-1′-coli and Campylobacter-1′-phytas. It is an object of the present invention to provide a method capable of rapidly detecting the presence of a target Campylobacter bacterium.
- the present inventors made a comparison with the CDT of C. jeju and C. fetus, and developed primers common to the three species of Campylobacter bacteria and primers specific to each of these bacteria. . It was also revealed that this primer can be applied to the multiplex PCR method, which can simultaneously and easily determine the presence or absence of Campylobacter bacteria CDT and identify the bacterial species, and can also be used for typing by PCR-RFLP method. .
- the present invention specifically includes the following technical embodiments:
- a method for detecting the presence of Campylobacter-1 'coli, Campylobacter-1'jeju-, and Campylobacter-1.Fetus in a test sample comprising the following steps (a) and (b): .
- a method for detecting the presence of Campylobacter-Cori, Campylobacter-Jeju, and Campylobacter-Fetus in a test sample including the following steps (a) to (c): Method.
- step (b) Using the genomic DNA amplified in step (a) as type I, a polymerase chain reaction using a mixture of primer pairs specific to each of the genomic DNAs encoding these bacterial swelling toxins is performed. Steps to perform
- the common primer pair is a primer pair selected from SEQ ID NO: 7-10, 47-50, or a primer pair capable of amplifying the same genomic DNA region as the primer pair; (8) The method described in 1.
- a primer pair selected from SEQ ID NO: 15, 16, 37-46, or the same as the primer pair, for amplifying genomic DNA encoding Campylobacter-1 ' Primer pairs that can amplify genomic DNA regions
- step (b) Step of cutting the genomic DNA amplified in step (a) with a restriction enzyme
- restriction enzyme selected from the group consisting of Sau3AI, DsaI, MboI, RsaI, EcoRI, HinfI, NdeI, PstI, XbaI, and XhoII. Method.
- a kit for use in the method according to (7) which comprises an instruction manual and cell swelling venom of Campylobacter-1.Coli, Campylobacter-1'Jeju-, and Campylobacter-1'Fetus.
- (15) Mixing power of specific ply pairs The kit according to (14), which is a ply pair of (a) to (c) below.
- a ply pair selected from SEQ ID NO: 15 16 37-46, or a genome identical to the primer pair, for amplifying genomic DNA encoding Campylobacter-1 ' Ply that can amplify DNA region vs. common ply
- cell swelling lethal toxin refers to a toxic factor belonging to the group of proteinaceous AB-type holotoxins, called cytolethal distending toxin (CDT or CLDT). This is also referred to as cell swelling lethal toxin (primary), cell swelling lethal toxin (primary), etc.
- Cell swelling dangling toxin has a submit structure consisting of three units of A, B and C, the B subunit is the central unit of toxin activity, and the A and B subunits are involved in cell adhesion It is believed that. When acting on cells, the cells are deformed such as greatly swelling, and eventually cause cell death.
- polynucleotide refers to a ribonucleotide or a deoxynucleotide, and refers to a polymer composed of a plurality of bases or base pairs.
- Polynucleotides include single-stranded and double-stranded DNA.
- a polynucleotide is meant to include both modified, unmodified, and modified, from the state they exist in nature.
- Modified bases include, for example, trityled bases and special bases such as inosine.
- polypeptide refers to a polymer comprising a plurality of amino acids. means. Therefore, oligopeptides and proteins are also included in the concept of polypeptide. Polypeptides are meant to include both those that are unmodified from the naturally occurring state and those that are modified.
- Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent binding of flavin, covalent bonding of the heme moiety, covalent bonding of nucleotides or nucleotide derivatives, covalent bonding of lipids or lipid derivatives, phosphatidylinositol Covalent bonds, crosslinks, cyclizations, formation of disulfide bonds, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, y-carboxylation, glycosylation, GPI anchor formation, hydroxylation, Transfer of amino acids to proteins such as iodination, methylation, myristylation, oxidation, proteolytic treatment, phosphorylation, prenylation, racemization, selenoylation, sulphation, arginylation, RNA-mediated addition, ubiquitination And so on.
- isolated refers to a substance (for example, a polynucleotide or a polypeptide) extracted from an original environment (for example, if it occurs naturally, its natural environment) and its natural state. Was changed "by the hand of man.” "Isolated” is meant to include compounds present in a sample substantially enriched for the compound of interest and compounds present in a sample in which Z or the compound of interest is partially or substantially purified. .
- substantially purified refers to a material that is at least 60%, preferably 75%, and most preferably 90% free of other components that are naturally related, with their natural environmental forces also being cut off. Refers to a compound (eg, a polynucleotide or polypeptide).
- mutant refers to an amino acid change in an amino acid sequence or a base change in a nucleotide sequence (ie, single or multiple amino acid or nucleotide substitution, deletion, addition or insertion). Point to. Therefore, the term “variant” as used herein refers to an amino acid sequence in which one or more amino acids are changed or a nucleotide sequence in which one or more bases are changed. Changes in the nucleotide sequence of this variant may or may not alter the amino acid sequence of the polypeptide encoded by the reference polynucleotide. The mutant may be a naturally occurring one, such as an allelic mutant, or a mutant that is not known to occur naturally.
- a variant may have conservative changes in which the substituted amino acid has similar structural or chemical properties. Rarely, mutants are non-conservative It may have substitutions.
- Guidance on determining which, and how many amino acid residues are substituted, inserted, or deleted, without inhibiting biological or immunological activity, can be found in computer programs well known in the art, For example, it can be found using DN's software.
- a “deletion” is one in which one or more amino acids or nucleotide residues are not present, respectively, as compared to the amino acid sequence or nucleotide sequence of the naturally occurring cell swelling lethal toxin polypeptide. , Amino acid or nucleotide sequence changes.
- “Insertion” or “addition” refers to an amino acid to which one or more amino acids or nucleotide residues have been added, respectively, as compared to the amino acid sequence or nucleotide sequence of a naturally occurring cell swelling polypeptide. Or a change in the nucleotide sequence.
- substitution means that one or more amino acids or nucleotides has been replaced with a different amino acid or nucleotide, respectively, as compared to the amino acid sequence or nucleotide sequence of a naturally occurring cell swelling polypeptide. An amino acid or nucleotide sequence change.
- hybridize refers to the process by which a nucleic acid strand binds to a complementary strand through base pairing.
- FIG. 1 is a photograph showing the results of PCR using GNW and LPF-D primers and a C. coli Col-192 cell extract as a template.
- Arrow 1 indicates the band (approximately 1.5 Kb) in which the cdt region was amplified, and band 2 (800 bp) indicates the secondary band derived from cdtB that was amplified because the GNW primer was a mixed primer.
- FIG. 2 is a photograph showing the results of hybridization after digestion of the genome of C. coli Col-192 cells with the restriction enzyme Hindlll.
- FIG. 3 is a photograph showing a result of PCR using common primer 1. A band derived from CDT is observed around 1.9 kbp in lanes 2-6.
- FIG. 4 is a photograph showing the results of PCR of various C. ziju strains using common primer 2. A band derived from CDT is observed around 720 bp.
- FIG. 6 is a photograph showing the results of PCR of a C. ziju strain, a C. coli strain, and a C. fetus strain using common primer 2.
- FIG. 7 is a photograph showing the results of multiplex PCR of C. jeju strain, C. coli strain, and C. fetus strain using specific primers. Unique CDT specific amplification fragments each species was observed (C. Jeju -: 7 50bp, C. coli: 400 bp, C. fetus: 5 30 bp).
- FIG. 8 is a photograph showing the results of PCR-RFLP of C. ziju strain, C. coli strain, and C. fetus strain using common primer 1.
- FIG. 9 is a photograph showing the results of multiplex PCR of various C. jeju strains, C. coli strains, and C. fetus strains using specific primers. A CDT-specific amplified fragment specific to each strain was confirmed (C. jeju-: 750 bp, C. coli: 400 bp, C. fetus: 530 bp).
- FIG. 10 is a photograph showing the results of hybridization after digestion with HindIII, a restriction enzyme of the genome of C. fetus Coat 187 cells.
- FIG. ll A photograph showing the results of PCR using cdtA and cdtC common primers. A band derived from cdtA is observed around 550 bp in lanes 2-8, and a band derived from cdtC is observed around 320 bp in lanes 10-16.
- FIG. 12 is a photograph showing the results of PCR of various Campylobacter strains using the cdtA common primer. A band derived from CdtA is observed around 550 bp.
- FIG. 13 is a photograph showing the results of PCR of various Campylobacter strains using the cdtC common primer. A band derived from cdtC is observed around 320 bp.
- FIG. 14 is a photograph showing the results of multiplex PCR of C. ziju strain, C. coli strain, and C. fetus strain using cdtA and cdtC specific primers.
- CdtA-specific amplified fragments C. digella: 630 bp, C. coli: 330 bp, C. fetus: 490 bp
- cdtC-specific fragments C. jeju-: 500 bp, C. coli: 400 bp
- FIG. 15 is a photograph showing the results of multiplex PCR of C. jeju-, C. coli, and C. phytas strains using cdtA-specific primers. CdtA unique to each strain Specific amplified fragments were confirmed.
- FIG. 16 is a photograph showing the results of multiplex PCR of C. jeju strain, C. coli strain, and C. phytas strain using cdtC-specific primers. CdtC-specific amplified fragments specific to each strain were confirmed.
- FIG. 17 is a view showing an ORF of C. jejuni and an anneal region of a primer.
- FIG. 18 is a view showing an ORF of C. coli and an anneal region of a primer.
- FIG. 19 is a view showing an ORF of C. fetus and an anneal region of a primer.
- the present invention provides a polynucleotide that encodes a Campylobacter ′ coli cell swelling toxin.
- the nucleotide sequence of the polynucleotide encoding the cell swelling of Campylobacter ′ identified by the present inventors, which is included in the present invention, is represented by SEQ ID NO: 1, and the three polynucleotides encoded by the polynucleotide are shown in SEQ ID NO: 1.
- the amino acid sequences of the peptides are shown in SEQ ID NOs: 2 to 4.
- SEQ ID NO: 2 is the amino acid sequence of cdtA
- SEQ ID NO: 3 is the amino acid sequence of cdtB
- SEQ ID NO: 4 is the amino acid sequence of cdtC.
- the present invention also provides a polynucleotide encoding the cell swelling venom of Campylobacter-1'fetus.
- the base sequence of the polynucleotide encoding the cell swelling venom of Campylobacter fetus identified by the present inventors included in the present invention is represented by SEQ ID NO: 51, and the three polynucleotides encoded by the polynucleotide are shown in SEQ ID NO: 51.
- the amino acid sequence of the peptide is shown in SEQ ID NOs: 52 to 54.
- SEQ ID NO: 52 is the amino acid sequence of cdtA
- SEQ ID NO: 53 is the amino acid sequence of cdtB
- SEQ ID NO: 54 is the amino acid sequence of cdtC.
- the polynucleotide of the present invention includes a polynucleotide encoding the polypeptide having the amino acid sequence described in SEQ ID NO: 2, and the coding region of the base sequence described in SEQ ID NO: 1, ie, SEQ ID NO: A polynucleotide comprising a base sequence from position 1 to position 777, a base sequence from position 802 to position 1605, or a base sequence from position 1615 to position 2187 in the base sequence described in 1.
- a polynucleotide encoding a polypeptide consisting of the amino acid sequence described in SEQ ID NO: 2 but having a nucleotide sequence different from the nucleotide sequence described in SEQ ID NO: 1 due to the degeneracy of the genetic code is included.
- the polynucleotide of the present invention also includes a polynucleotide encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO: 52 to 54, the coding region of the nucleotide sequence of SEQ ID NO: 51, ie, SEQ ID NO: 51
- a polynucleotide comprising the nucleotide sequence from position 1 to position 702, the nucleotide sequence from position 778 to position 1629, or the nucleotide sequence from position 1615 to position 2187 in the nucleotide sequence described in 1.
- the polynucleotide of the present invention further encodes a polypeptide functionally equivalent to the polypeptide encoded by these polynucleotides, and at least 40% or more, preferably, 60% or more, more preferably 80% or more, further preferably 90% or more, more preferably 95% or more, and even more preferably 97% or more (for example, 98-99%). It is. Nucleotide sequence identity can be determined, for example, by the algorithm BLAST by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87: 2264-2268, 1990, Proc. Natl. Acad. Sci. USA 90: 5873-5877, 1993). ) Can be determined.
- the polynucleotide of the present invention includes a polynucleotide having a base sequence complementary to the base sequence of the above-mentioned polynucleotide.
- the polynucleotide of the present invention can also obtain a natural source such as, for example, genomic DNA in bacterial cells by standard closing and screening. Alternatively, it can be obtained from a cDNA library derived from mRNA in bacterial cells. It can also be synthesized using a commercially available known technique.
- Polynucleotides having significant nucleotide homology with the polynucleotide sequence (SEQ ID NO: 1, SEQ ID NO: 51) identified by the present inventors include, for example, No. Protocols in Molecular Biology edit.Ausubel et al. (1987) Prepare using Publish. John Wiley & Sons Section 6.3-6.4) and gene amplification technology (PCR) (Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 6.1-6.4). be able to.
- the present invention includes a polynucleotide that hybridizes under stringent conditions with a polynucleotide having the nucleotide sequence of SEQ ID NO: 1.
- Stringent hybridization conditions are usually about lxSSC, 0.1% SDS, 37 ° C, and more stringent conditions are about 0.5xSSC, 0.1% SDS, 42 ° C. More severe conditions are the conditions of “0.2xSSC, 0.1% SDS, 65 ° C”. As described above, isolation of DNA having higher homology to the probe sequence can be expected as the hybridization conditions become more severe. However, the combination of the above SSC, SDS and temperature conditions is merely an example, and those skilled in the art will recognize the above or other factors (eg, probe concentration, probe length, etc.) that determine the stringency of the hybridization. , Hybridization reaction time, etc.) as appropriate, it is possible to realize the same stringency as described above.
- factors eg, probe concentration, probe length, etc.
- a polynucleotide consisting of a nucleotide sequence having significant homology to the polynucleotide sequence identified by the present inventors can be obtained by a method for introducing a mutation into the nucleotide sequence described in SEQ ID NO: 1 or SEQ ID NO: 51 (for example, It can also be prepared using site-directed mutagenesis (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 8.1-8.5). Such polynucleotides may also be caused by mutations in nature.
- polynucleotide of the present invention includes the coding sequence of the mature polypeptide or a fragment thereof alone, or another coding sequence (for example, A coding sequence for a mature polypeptide or a fragment thereof that is in the same reading frame as the leader or secretory sequence, one that encodes a pre-, pro- or pre-proprotein sequence, or other fusion peptide portion.
- a marker sequence that facilitates purification of the fusion polypeptide can be encoded.
- the marker sequence is provided by the pcDNA3.1 / Myc-His vector (Invitrogen) and Gentz et al., Proc. Natl. Acad. Sci. USA (1989) 86: 821- Hexa-histidine peptide, as described in 824, or a Myc tag.
- the polynucleotide also includes 5 'and 3' non-coding sequences, such as transcribed but not translated sequences, splicing and polyadenylation signals, ribosome binding sites, and mRNA stabilizing sequences! / You can! / ,.
- the present invention provides a polypeptide of the cell swelling and killing toxin of Campylobacter ′ ′ coli identified by the present inventors. Further, the present invention provides polypeptides that are functionally equivalent to the polypeptides identified by the present inventors.
- “functionally equivalent” means that the target polypeptide has the same cell swelling and killing toxin characteristics as the polypeptide identified by the present inventors.
- the present invention also provides a polypeptide of Campylobacter 1'fetus identified by the present inventors, which is a cell swelling and killing toxin. Further, the present invention provides polypeptides that are functionally equivalent to the polypeptides identified by the present inventors.
- “functionally equivalent” means that the polypeptide of interest has the same property of lethal toxin as a cell swelling equivalent to the polypeptide identified by the present inventors.
- One embodiment of a method for preparing a polypeptide functionally equivalent to the polypeptide identified by the present inventors includes a method of introducing a mutation into an amino acid sequence in a protein. Such methods include, for example, site-directed mutagenesis (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publisn. Jhon Wily & Sons Section 8.1-8.5). In addition, mutation of amino acids in polypeptides In some cases.
- the present invention includes the amino acid sequence of the polypeptide identified by the present inventors (SEQ ID NO: 2, SEQ ID NO: 52 to 54), whether artificial or natural. And a polypeptide in which one or more amino acids are mutated by substitution, deletion, insertion, Z or addition, and the like, and include polypeptides functionally equivalent to the polypeptide identified by the present inventors.
- the amino acid to be substituted is preferably an amino acid having properties similar to the amino acid before substitution from the viewpoint of maintaining the function of the protein (conservative substitution).
- Ala, Val, Leu, Ile, Pro, Met, Phe, and Trp are considered to have similar properties because they are all classified as non-polar amino acids.
- examples of the non-charger include Gly, Ser, Thr, Cys, Tyr, Asn, and Gin.
- acidic amino acids include Asp and Glu
- examples of basic amino acids include Lys, Arg, and His.
- the number of amino acid mutations and mutation sites in these polypeptides are not limited as long as their functions are maintained.
- the number of mutations is typically considered to be within 10% of all amino acids, preferably within 5% of all amino acids, and more preferably within 1% of all amino acids.
- a polypeptide encoded by a DNA that hybridizes to a DNA encoding the polypeptide identified by the present inventors, wherein the polypeptide is functionally equivalent to the polypeptide identified by the present inventors. are also included in the polypeptides of the present invention.
- Stringent hybridization conditions for isolating DNA are generally ⁇ lxSSC, 0.1% SDS, 37 ° C '', and more stringent conditions are ⁇ 0.5xSSC, 0.1% SDS , 42 ° C ”, and more severe conditions are“ 0.2xSSC, 0.1% SDS, 65 ° C ”.
- isolation of DNA having high homology with the probe sequence can be expected as the hybridization conditions become more severe.
- the combination of the above SSC, SDS and temperature conditions is merely an example, and those skilled in the art will recognize the above or other factors (for example, probe concentration, protein concentration, etc.) that determine the stringency of the hybridization. By appropriately combining the length of the probe and the hybridization reaction time, it is possible to realize the same stringency as described above.
- a polypeptide encoded by DNA isolated using such a hybridization technique usually has high homology in amino acid sequence with the polypeptide identified by the present inventors.
- High homology means at least 40% or more, preferably 60% or more, more preferably 80% or more, more preferably 90% or more, more preferably at least 95% or more, and even more preferably at least 97% or more (for example, , 98-99%).
- the amino acid sequence identity can be determined, for example, by the algorithm BLAST by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87: 2264-2268, 1990, Proc. Natl. Acad. Sci. USA 90: 5873-5877, 1993). Can be determined by A program called BLASTX has been developed based on this algorithm (Altschul et al. J. Mol.
- the present invention also provides fragments of the polypeptide of the present invention.
- a fragment is a polypeptide having an amino acid sequence that is not entirely identical to a portion of the amino acid sequence of the polypeptide of the present invention.
- the polypeptide fragment of the present invention is usually a polypeptide fragment having a sequence of 8 amino acid residues or more, preferably 12 amino acid residues or more (for example, 15 amino acid residues or more).
- Suitable fragments include, for example, a deletion of a series of residues including the amino terminus or a series of residues including the carboxyl terminus, or a combination of a series of residues including the amino terminus and a series of residues including the carboxyl terminus.
- truncation polypeptides having an amino acid sequence with truncated residues deleted.
- fragments characterized by structural or functional properties such as those that contain variable regions, surface forming regions, substrate binding regions, and high antigen index regions.
- Other suitable fragments are biologically active fragments.
- Biologically active fragments are those that mediate the activity of a polypeptide of the present invention, including those with similar activity, those with enhanced activity, or those with reduced undesirable activity.
- fragments that are antigenic or immunogenic in animals, particularly humans are also included. These polypeptide fragments preferably retain the biological activity of the polypeptide of the present invention, including the antigen activity.
- Variants of the specified sequences and fragments also form part of the invention. Preferred variants are those that differ from the subject by conservative amino acid substitutions, ie, those that substitute a residue with another residue of similar properties. Typical such substitutions are between Ala, Val, Leu and lie, between Ser and Thr, between the acidic residues Asp and Glu, between Asn and Gin, between the basic residues Lys and Arg, or aromatic. Occurs between group residues Phe and Tyr.
- polypeptide of the present invention can be produced by any appropriate method.
- polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or a combination of these methods. Polypeptides are included. Means for the production of such polypeptides are Well understood in the industry.
- Recombinant polypeptides can be prepared, for example, by introducing a vector into which a polynucleotide of the present invention has been inserted into an appropriate host cell, and purifying the polypeptide expressed in the transformant.
- a naturally occurring polypeptide can be prepared, for example, using an affinity column to which an antibody against the polypeptide of the present invention described below is bound (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 16.1—16.19).
- the antibody used for affinity purification may be a polyclonal antibody or a monoclonal antibody.
- in vitro translation for example, “On the fidelity of mRNA translation in the nuclease—treated rabbit reticulocyte lysate system.
- a fragment of the polypeptide of the present invention can be produced, for example, by cleaving the polypeptide of the present invention with an appropriate peptidase.
- the present invention relates to a polynucleotide identified by the present inventors (a polynucleotide comprising the base sequence of SEQ ID NO: 1 or a complementary strand thereof, a polynucleotide comprising the base sequence of SEQ ID NO: 51 or a complement thereof) And a nucleotide having a chain length of at least 15 nucleotides that is complementary to
- the “complementary strand” refers to one strand of a double-stranded nucleic acid having the base pair force of A: T (U for RNA) and G: C.
- nucleotide is not limited to a case where the sequence is completely complementary to at least 15 contiguous nucleotide regions, but is at least 70%, preferably at least 80%, more preferably 90%, and still more preferably What is necessary is that it has at least 95% nucleotide sequence homology!
- the algorithm described in the present specification may be used as an algorithm for determining homology.
- Such a nucleotide can be used as a probe for detecting and isolating the polynucleotide of the present invention, and as a primer for amplifying the nucleotide of the present invention. When used as a primer, it usually has a chain length of 15 to 100 nucleotides, preferably 15 to 35 nucleotides.
- the type of the nucleic acid amplification reaction is not particularly limited as long as the desired amplification product can be obtained.
- the method can be selected from a DNA amplification reaction such as a PCR (polymerase chain reaction) method, an ICAN method, a LAMP method, an SDA method, an LCR method, and an RNA amplification reaction such as a NASBA method.
- a PCR method can be shown as a suitable method.
- nucleotide is specific to DNA encoding the polypeptide of the present invention.
- “Specific” refers to a DNA that hybridizes with DNA encoding a particular polypeptide under normal hybridization conditions, preferably under stringent conditions, with DNA encoding another polypeptide. Means do not hybridize.
- the embodiment hybridizes to genomic DNA (SEQ ID NO: 1) that encodes Campylobacter 'coli cell swelling toxin and encodes Campylobacter' Jeju- and Campylobacter ⁇ ⁇ ⁇ phytas cell swelling toxin. It does not hybridize with genomic DNA! /! Polynucleotide.
- Such polynucleotides include, for example, primer pairs selected from SEQ ID NO: 13, 14, 28-36, 70, 71, 76, 77.
- a preferred embodiment is a cell swelling of Campylobacter-1'fetus which hybridizes to the genomic DNA encoding the killing toxin (SEQ ID NO: 51) and causes the cell expansion of Campylobacter-1'jeju- and Campibacterium-coli.
- It is a polynucleotide that does not hybridize with the genomic DNA encoding the killing toxin.
- Such polynucleotides include, for example, primer pairs selected from SEQ ID NOs: 15, 16, 37-46, 72, 73, 78, 79.
- the genomic DNA (SEQ ID NO: 1) encoding the cell swelling of Campylobacter 1 ′ E. coli was clarified, and the cells of Campylobacter 1 ′ Jeju2 were identified.
- the present inventors have found out a base sequence specific to genomic DNA encoding the swelling toxin and the genomic DNA encoding a swelling toxin of Campylobacter fetus. Therefore, the present invention provides a primer pair specific to genomic DNA encoding Campylobacter 1'-jujuj's cell swelling lethal toxin and a genomic DNA encoding campylobacter 1 'phytas cell swelling toxin. A primer pair is also provided.
- primers specific to genomic DNA encoding Campylobacter 1'jeju2's cell swelling killer toxin include primers described in SEQ ID NOS: 11, 12, 17-27.
- Primers specific to genomic DNA coding for Campylobacter 1'Fetus cell swelling killer toxin include, for example, primers described in SEQ ID NOs: 15, 16, 37-46. Not restricted.
- genomic DNA (SEQ ID NO: 1) encoding cell swelling killing toxin of Campylobacter I'coli and genome encoding cell swelling killing toxin of Campylobacter 1'fetus
- the present inventor has proposed that the genomic DNA encoding the cell swelling toxin of Campylobacter 1. coli, Campylobacter 1'Jeju2, and Campylobacter 1'Fetus (Primers capable of amplifying genomic DNA encoding cell swelling toxin of all these bacteria) were found.
- the present invention also provides such a common primer.
- Preferred common primers include, for example, the primers described in SEQ ID NOs: 64 and 65 (amplifying ctdA DNA), the SEQ ID NOs: primers described in 7-10 and 47-50 (amplifying ctdB DNA), SEQ ID NO: Primers described in 66 and 67 (amplifying ctdC DNA).
- the nucleic acid amplification reaction to which the primer of the present invention can be applied is not particularly limited as long as the desired amplification product can be obtained.
- PCR polymerase chain reaction
- ICAN ICAN
- LAMP amino acid amplification
- SDA SDA
- the neutral strength of DNA amplification reaction such as LCR method and RNA amplification reaction such as NASBA method.
- a PCR method can be shown as a suitable method.
- a person skilled in the art can also design a mutation primer suitable for the nucleic acid amplification method to be performed, based on the primer.
- Mutant primers can be prepared synthetically. Whether the mutated primer can amplify the same genomic DNA region as the unmutated primer can be easily evaluated by performing a nucleic acid amplification reaction using the mutated primer and analyzing the amplification product. .
- These primers can be suitably used for detecting the presence of Helicobacter bacteria in a test sample. ⁇ Production of Vector, Host Cell, and Polypeptide>
- the present invention also provides a vector containing the polynucleotide of the present invention, the polynucleotide of the present invention or a host cell carrying the vector, and a method for producing the polypeptide of the present invention using the host cell.
- the vector of the present invention is not particularly limited as long as it can stably maintain the inserted DNA.
- the closing vector is a pBluescript vector (manufactured by Stratagene). Is preferred! / ,.
- an expression vector is particularly useful.
- the expression vector is not particularly limited as long as it expresses the polypeptide in a test tube, in Escherichia coli, in cultured cells, or in an individual organism. Examples of the expression vector include a pBEST vector (manufactured by Promega) for expression in a test tube.
- pET vector manufactured by Invitrogen
- PME18S-FL3 vector GeneBank Accession No. AB009864
- PME18S vector Mol Cell Biol. 8: 466-472 (1988)
- Insertion of the DNA of the present invention into a vector can be performed by a conventional method, for example, by a ligase reaction using a restriction enzyme site (Current protocols in Molecular Biology edit.Ausubel et al. (1987) Publish. John Wiley & Sons. Section 11.4—11.11).
- the host cell into which the vector of the present invention is introduced is not particularly limited, and various host cells may be used depending on the purpose.
- Cells for expressing the polypeptide include, for example, bacterial cells (eg, Streptococcus, Staphylococcus, Escherichia coli, Streptomyces, Bacillus subtilis), fungal cells (eg, yeast, Aspergillus), insect cells (eg, Drosophila S2) , Spodoptera SF9), animal cells (eg, CHO, COS, HeLa, C127, 3T3, BHK, HEK293, Bowes melanoma cells) and plant cells.
- Vectors can be introduced into host cells by, for example, calcium phosphate precipitation, electropulse perforation (Current protocols in
- an appropriate secretion signal is added to the target polypeptide.
- These signals may be endogenous to the polypeptide of interest or heterologous signals.
- polypeptide of the present invention is recovered when the polypeptide of the present invention is secreted into the medium.
- the recombinant cell culture medium In order to recover and purify the polypeptide of the present invention, the recombinant cell culture medium also needs ammonium sulfate sulfate.
- antibody includes polyclonal and monoclonal antibodies, chimeric antibodies, single-chain antibodies, humanized antibodies, as well as Fab fragments containing Fab or other products of an immunoglobulin expression library.
- the polypeptide of the present invention or a fragment or analog thereof, or a cell expressing the same can also be used as an immunogen for producing an antibody that binds to the polypeptide of the present invention.
- the antibodies are preferably immunospecific for a polypeptide of the invention. "Immunospecific" means that the antibody has a substantially higher affinity for the polypeptide of the invention than for its affinity for other polypeptides.
- Antibodies that bind to the polypeptide of the present invention can be prepared by methods known to those skilled in the art.
- a polyclonal antibody can be obtained, for example, as follows.
- the polypeptide of the present invention or its fusion protein with GST is immunized to small animals such as egrets to obtain serum.
- This is prepared by, for example, purification using ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography, an affinity column to which the polypeptide of the present invention is coupled, and the like.
- a monoclonal antibody for example, a small animal such as a mouse is immunized with the polypeptide of the present invention, a spleen is excised from the mouse, and the spleen is crushed to separate cells.
- a clone that produces an antibody that binds to the polypeptide of the present invention is selected from fusion cells (hybridomas) obtained by fusion with a reagent such as glycol.
- the obtained no and ibridomas are transplanted intraperitoneally into the mouse, ascites is collected from the mouse, and the obtained monoclonal antibody is subjected to, for example, ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography. Alternatively, it can be prepared by purifying with an affinity column or the like to which the polypeptide of the present invention has been coupled.
- the antibody of the present invention is used for detecting or purifying the polypeptide of the present invention in a test sample.
- the present invention provides a method for detecting the presence of Campylobacter bacteria in a test sample. Detection of the presence of Campylobacter bacteria in the test sample can be performed in various ways, including diagnosis of Campylobacter infection, rapid diagnosis of foods contaminated with Campylobacter bacteria, validation of food processing processes, and identification of the causative organism when food poisoning occurs. It is useful for the purpose of.
- One embodiment of the detection method of the present invention is a method for detecting the presence of Campylobacter 1 'coli, Campylobacter 1' jeju-, and Campylobacter 1 'feedus in a test sample, wherein (a) Performing a polymerase chain reaction on the test sample using a mixture of primer pairs specific to each of the genomic DNAs encoding the killing toxin of these bacteria; and (b) cell swelling of these bacteria. Determining the presence of these bacteria from the presence or absence or the molecular weight of the amplified fragment of the genomic DNA encoding the dangling toxin.
- Another aspect of the detection method of the present invention is a method for detecting the presence of Campylobacter-1 ′ coli, Campylobacter-1′jeju-, and Campylobacter-1′fetus in a test sample, (A) a step of subjecting a test sample to a nucleic acid amplification reaction using a common primer pair capable of amplifying genomic DNA encoding the bacterial cell swelling toxin of these bacteria; Performing a polymerase chain reaction using a mixture of primer pairs specific for each of the genomic DNAs encoding the bacterial swelling lethal toxin of these bacteria with the obtained genomic DNA, and (c) Genome coding for cell swelling dangling toxin Determining the presence of these bacteria from the presence or absence or the molecular weight of the amplified DNA fragment.
- PCR using a plurality of PCR primers in a single reaction system is referred to as a multiplex PCR method. Species can be identified simultaneously.
- the present invention provides primers suitably used for amplification of a plurality of nucleic acid regions, and a method for detecting Campylobacter bacteria by a nucleic acid amplification method using a combination thereof, typified by the multiplex PCR method.
- the method of nucleic acid amplification in the present invention is not particularly limited as long as the desired amplified product can be obtained, and is preferably a PCR method.
- primer pairs for example, the following mixture of primer pairs of (a) strength and (c) can be used.
- a primer pair or a primer pair capable of amplifying the same genomic DNA region as the primer pair (c) SEQ ID NO: 15, for amplifying genomic DNA encoding cell swelling toxin of Campylobacter i'fetus; A primer pair selected from 16, 37-46, or a primer pair capable of amplifying the same genomic DNA region as the primer pair.
- the common primer pair for example, a primer pair selected from SEQ ID NOs: 7-10, 47-50, or a primer pair capable of amplifying the same genomic DNA region as the primer pair can be used. .
- a further embodiment of the detection method of the present invention is a method for detecting the presence of Campylobacter 1'coli, Campylobacter 1.jeju2, and Campylobacter 1'Fetus in a test sample, the method comprising: Performing, on the test sample, a nucleic acid amplification reaction using a common primer pair capable of amplifying genomic DNA encoding the bacterial swelling toxin of these bacteria, (b) genomic DNA amplified in step (a) A method comprising the steps of: cleaving with a restriction enzyme; and (c) determining the presence of these bacteria from the molecular weight of the cleaved DNA fragment.
- Restriction enzymes that can be used are not particularly limited as long as they can identify genomic DNAs encoding Campylobacter-'Coli, Campylobacter-'Jeju-, and Campylobacter-'Fetus cell swelling toxin. , Sau3AI, DsaI, MboI, RsaI, EcoRI, HinfI, NdeI, PstI, XbaI, XhoII.
- Examples of the common primer pair include a primer pair selected from SEQ ID NOs: 7-10 and 47-50, and a primer pair capable of amplifying the same genomic DNA region as the primer pair.
- a method of treating DNA amplified by the PCR method with various restriction enzymes and detecting a polymorphism from the length of the generated fragment is a PCR-RFLP method (PCR-Restriction Fragment Length Polymorphism: PCR-restriction fragment length polymorphism).
- the present invention also relates to a primer suitably used in a method of treating DNA amplified by a nucleic acid amplification method with various restriction enzymes, such as a PCR-RFLP method, and detecting a polymorphism from the length of a generated fragment. I will provide a.
- Another embodiment of the detection method of the present invention is a method for detecting the presence of Campylobacter bacteria in a test sample, wherein (a) cell swelling of Campylobacter bacteria relative to the test sample is performed. Performing a nucleic acid amplification reaction using a common primer pair that can amplify genomic DNA encoding lethal toxin
- the primer pair used in this method is a primer pair capable of amplifying genomic DNA encoding the cell swelling toxin, regardless of the species of the genus Campylobacter.
- Examples of such a common primer pair include a primer pair selected from SEQ ID NO: 7-10, 47-50, 64-67.
- the above primer pair is a common primer pair that amplifies at least genomic DNA encoding cell swelling toxin of Campylobacter-1 ′ coli, Campylobacter-1 ′ jeju2 and Campylobacter fetus3. is there.
- the above primer pair can be expected to amplify genomic DNA encoding not only the above three bacterial species but also the cell swelling toxin of Campylobacter.
- the genomic region can be amplified by sharing the above three strains. It is believed that the genomic region of other Campylobacter bacteria can be amplified.
- the present invention also provides a kit for use in the above-described detection method of the present invention.
- kits include instructions for use in addition to the primer pairs described above. It may contain still other elements.
- Campylobacter bacteria may be detected not only at the DNA level but also at the protein level. For example, using an antibody specific to the cell swelling of these bacteria, Western blotting, dot blotting, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), or immunofluorescence, etc. It is possible to evaluate the presence of these bacteria in the test sample by carrying out and detecting the cell swelling of these bacteria.
- an antibody specific to the cell swelling of these bacteria Western blotting, dot blotting, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), or immunofluorescence, etc. It is possible to evaluate the presence of these bacteria in the test sample by carrying out and detecting the cell swelling of these bacteria.
- the cells were cultured using a culture device (MODEL9200: Wakken Yakuhin).
- the C. coli cdtB probe was prepared by PCR labeling using GNW and LPF-D primers and a DIG labeling mix (Roche) using C. coli Col-192 cell extract as a template.
- the amplified band was ligated to a pT7 vector (Novagen) and the host E. coli (E. coli) was ligated.
- a 3k44 clone containing the C. coli cdtB region obtained in Example 3 was sequenced by a conventional method to determine the sequence of the entire C. coli CDT region represented by SEQ ID NO: 1.
- the following common primer U and common primer R were designed by comparing the C. coli CDT sequence of the present invention with the CDT gene of C. gingivali obtained from a known database.
- the solution was adjusted to a volume of 20 L, and subjected to a PCR reaction under the conditions of 94 ° C for 3 minutes (94 ° C for 30 seconds, 55 ° C for 30 seconds, and 72 ° C for 1 minute) ⁇ 30 cycles of 72 ° C for 3 minutes.
- the results are shown in Figure 3.
- An amplified fragment of about 1900 bp was confirmed, and a band derived from CDT was observed in both C. jeju- (lanes 2 to 4) and C. coli (lanes 5 and 6).
- C. jeju-specific primers QSPBU3 and QSPBR3 were designed by comparing the C. coli CDT sequence of the present invention with the CDT gene of C. gejudin obtained from a known database. Similarly, C. coli-specific primers CcSPBU5 and CcSPBR5, and C. fetus-specific primers CSPBUl and CSPBRl were designed.
- Example 7 Multiplex PCR was performed using the specific primers obtained in Example 7 and various clinical strains of Campylobacter under the experimental conditions of Example 7.
- Figure 9 shows the results.
- C. jeju-CDT-specific amplified fragment about 750 bp
- C. coli CDT-specific amplified fragment about 400 bp
- C. fetus CDT-specific amplified fragment about 530 bp
- the C. fetus cdtB probe was subjected to PCR labeling using DIG labeling mix (Roche) using common primer 2 (common primer Up and common primer Do) and C. fetus Col-187 cell extract as a template.
- DIG labeling mix Roche
- common primer 2 common primer Up and common primer Do
- C. fetus Col-187 cell extract was produced.
- the genome g of C. fetus Col-187 was digested with 60 U of restriction enzyme Hindlll at 37 ° C. for 12 hours, followed by a conventional method (Molecular cloning: a laboratory manual, Cold Spring Harbor Labolatory, Cold Spring Blot and DNA-DNA hybridization were performed according to Spring Harbor, (2001). Hybridization was performed at 42 ° C under stringent conditions.
- the Cf78 clone containing the C. fetus cdtB region obtained in Example 10 was sequenced by a conventional method, and the sequences of the cdtA and cdtB regions of C. fetus were determined.
- the obtained clone Cf78 did not contain the cdtC region! /, So the gene was walked under the following conditions using random primers designed from the determined cdtB gene sequence, and the sequence of the cdtC region was determined. Then, the sequence of the entire region of C. fetus CDT represented by SEQ ID NO: 51 was determined.
- Example 11 Based on the gene sequence obtained in Example 11, a set of the following random primer, target amplification primer and sequence primer was designed, and the target was amplified using the gene of C. fetus Coat 187 as a template. To amplify the target, add lOpmol of random primers to 20 ng of the template gene, adjust to a final volume of 100 L using KOD Dash PCR Kit (Toyobo), and heat at 94 ° C for 2 minutes (94 ° C for 20 seconds). , 65 ° C. for 5 seconds, 74 ° C. for 30 seconds) ⁇ 35 cycles.
- KOD Dash PCR Kit Toyobo
- the obtained PCR product was subjected to a sequence according to a standard method using a sequence primer.
- Random primer Own column number 55 GCTTGTAGCAGTATTGATGCNNNNNNNNN]
- Target amplification primer Own column number 56 GCTTGTAGCAGTATTGATGC]
- Random primer Own column number 58 ATACGCAATGCAAACACCGGNNNNNNNNN]
- Target amplification primer Own column number 59 ATACGCAATGAAACACCGG]
- Sequence primer [SEQ ID NO: 60: TAAAAGCGATTTTCAGGGCAG] Primer set 3
- Random primer Own column number 61 TGTCGACATAGAGCCTAAACNNNNNNN]
- Target amplification primer Own column number 62 TGTCGACATAGAGCCTAAAC]
- the cdtA sequence of C. coli and C. fetus of the present invention was compared with the cdtA gene of C. gingivali obtained from a known database, and the following common primers U and R of cdtA were designed. 1 ⁇ L of 20 ⁇ ⁇ / / ⁇ L bacterial cell extract, each primer was mixed to a concentration of 0.25mM, and then added to the mixture.
- a PCR reaction buffer (TaKaRa Ex Taq kit: Takara Bio) was adjusted to a final volume of 20 L using a PCR, and subjected to a PCR reaction under the conditions of 94 ° C for 3 minutes— (94 ° C for 30 seconds, 55 ° C for 30 seconds, 72 ° C for 30 seconds) X 30 cycles at 72 ° C for 3 minutes .
- the results are shown in Fig. 11 (left).
- An amplified fragment of about 550 bp was confirmed, and a band derived from cdtA was observed in all of C. jeju- (lanes 2-4), C. coli (lanes 5, 6), and C. fetus (lanes 7, 8).
- a PCR reaction buffer (TaKaRa Ex Taq kit: Takara Bio) was adjusted to a final volume of 20 L using a PCR, and subjected to a PCR reaction under the conditions of 94 ° C for 3 minutes— (94 ° C for 30 seconds,
- Example 12 shows the results. As in Example 12, a cdtA-specific amplified fragment (about 550 bp) was confirmed.
- Example 14 Design and PCR of common primer for cdtC
- the C. coli and C. fetus cdtC sequences of the present invention were compared with the cdtC gene of C. jejuni obtained from the known database (BLAST), and the following cdtC common primer U and cdtC common primer R were designed.
- a cdtC-specific amplified fragment (about 320 bp) was confirmed.
- C. jeju- and C. coli CDT genes obtained from a known database (BLAST)
- the following C. jeju-specific primers QASPU2 and QASPR2 were designed. did.
- C. coli-specific primers CcASPUl and CcASPRl and C. fetus-specific primers CfASPUl and CfASPRl were designed.
- each primer is mixed to a concentration of 0.125 mM, and then added to the mixture, followed by PCR reaction buffer (TaKaRa Ex Taq kit: TAKARA BIO) Adjust to a final volume of 20 L using the following procedure: 94 ° C for 3 minutes (94 ° C for 30 seconds, 55 ° C for 30 seconds, 72 ° C for 30 seconds) X 30 cycles For multiplex PCR at 72 ° C for 3 minutes Provided ( GeneAmp PCR System 9700: Applied Biosystems). The results are shown in Figure 14 (left). C. jeju-CDT specific amplified fragment (about 630 bp), C.
- Example 14 Using the specific primers obtained in the examples, various clinical strains of Campylobacter bacteria were subjected to multiplex PCR under the experimental conditions of the example 14. The results are shown in FIG. As in Example 14, a C. jeju-cdtA specific amplified fragment (about 630 bp), a C. coli cdtA specific amplified fragment (about 330 bp) and a C. fetus cdtA specific amplified fragment (about 490 bp) were confirmed. Thus, it was possible to identify each bacterial species.
- the C. fetus CDT sequence of the present invention was compared with the C. jejuni and C. coli CDT genes obtained from known databases, and the following C. jeju-specific primers were compared.
- CjCSPUl and QCSPR2 were designed.
- C. coli-specific primers CcCSPUl and CcCSPRl and C. fetus-specific primers CfCSPU2 and CfCSPRl were designed.
- Example 14 Multiplex PCR was performed using the specific primers obtained in the Examples and various clinical strains of the genus Campylobacucu under the experimental conditions of Example 14.
- Figure 16 shows the results.
- the C. geju-CdtC-specific amplified fragment about 500 bp
- the C. coli CdtC-specific immediate broad fragment about 300 bp
- the C. fetus CdtC-specific amplified fragment main about 400 bp
- the primer of the present invention can be used not only for epidemiological investigation and research of Campylobacter bacteria, and for diagnosis of Campylobacter infection, but also for rapid diagnosis of foods contaminated with Campylobacter bacteria, validation of food processing steps, food poisoning. It is possible to quickly identify the causative organism at the time of outbreak and is useful for preventing the spread of infection.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004800412576A CN1914322B (zh) | 2003-12-05 | 2004-12-03 | 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测 |
US10/581,757 US7563594B2 (en) | 2003-12-05 | 2004-12-03 | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
KR1020117028508A KR101202934B1 (ko) | 2003-12-05 | 2004-12-03 | 세포팽창화 치사독 및 그것을 표적으로 한 캄필로박터속에 속하는 세균의 검출 |
EP04819936.8A EP1698698B1 (en) | 2003-12-05 | 2004-12-03 | Cytolethal distending toxin genes as targets for the detection of campylobacter bacteria |
ES04819936.8T ES2456710T3 (es) | 2003-12-05 | 2004-12-03 | Genes de toxinas de distensión citoletales como dianas para la detección de bacterias Campylobacter |
DK04819936.8T DK1698698T3 (da) | 2003-12-05 | 2004-12-03 | Cytolethaldistenderende toksingener som mål for detektering af campylobacterbakterier |
KR1020067013342A KR101152078B1 (ko) | 2003-12-05 | 2004-12-03 | 세포팽창화 치사독 및 그것을 표적으로 한 캄필로박터속에속하는 세균의 검출 |
JP2005515991A JP4624927B2 (ja) | 2003-12-05 | 2004-12-03 | 細胞膨張化致死毒およびそれを標的としたカンピロバクター属に属する細菌の検出 |
CA2548381A CA2548381C (en) | 2003-12-05 | 2004-12-03 | Cytolethal distending toxins and detection of campylobacter bacteria using the same as a target |
AU2004295596A AU2004295596C1 (en) | 2003-12-05 | 2004-12-03 | Cytolethal distending toxins and detection of campylobacter bacteria using the same as a target |
US12/495,309 US8343723B2 (en) | 2003-12-05 | 2009-06-30 | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
US12/495,289 US8168408B2 (en) | 2003-12-05 | 2009-06-30 | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
US13/458,532 US8354500B2 (en) | 2003-12-05 | 2012-04-27 | Cytolethal distending toxins and detection of campylobacter bacteria using the same as a target |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-408103 | 2003-12-05 | ||
JP2003408103 | 2003-12-05 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/581,757 A-371-Of-International US7563594B2 (en) | 2003-12-05 | 2004-12-03 | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
US12/495,289 Division US8168408B2 (en) | 2003-12-05 | 2009-06-30 | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
US12/495,309 Division US8343723B2 (en) | 2003-12-05 | 2009-06-30 | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005054472A1 true WO2005054472A1 (ja) | 2005-06-16 |
Family
ID=34650335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018042 WO2005054472A1 (ja) | 2003-12-05 | 2004-12-03 | 細胞膨張化致死毒およびそれを標的としたカンピロバクター属に属する細菌の検出 |
Country Status (12)
Country | Link |
---|---|
US (4) | US7563594B2 (ja) |
EP (1) | EP1698698B1 (ja) |
JP (1) | JP4624927B2 (ja) |
KR (2) | KR101202934B1 (ja) |
CN (3) | CN103397041B (ja) |
AU (1) | AU2004295596C1 (ja) |
CA (2) | CA2903388C (ja) |
DK (1) | DK1698698T3 (ja) |
ES (1) | ES2456710T3 (ja) |
HK (2) | HK1170263A1 (ja) |
PT (1) | PT1698698E (ja) |
WO (1) | WO2005054472A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009028662A1 (ja) | 2007-08-31 | 2009-03-05 | Osaka Prefecture University | 細胞膨張化致死毒を標的としたカンピロバクター属細菌の検出 |
JP2010130901A (ja) * | 2007-08-24 | 2010-06-17 | Osaka Prefecture Univ | 細胞膨張化致死毒を標的としたカンピロバクター属細菌の検出 |
US8168408B2 (en) | 2003-12-05 | 2012-05-01 | Fuso Pharmaceutical Industries, Ltd. | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
US9200330B2 (en) | 2007-08-24 | 2015-12-01 | Osaka Prefecture University | Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin |
JP2016086754A (ja) * | 2014-11-06 | 2016-05-23 | Jnc株式会社 | カンピロバクター検出用培地 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11693009B2 (en) * | 2009-02-11 | 2023-07-04 | Cedars-Sinai Medical Center | Methods for detecting post-infectious irritable bowel syndrome |
WO2010093776A1 (en) * | 2009-02-11 | 2010-08-19 | Cedars-Sinai Medical Center | Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome |
NO2396652T3 (ja) * | 2009-02-11 | 2018-05-12 | ||
KR102203568B1 (ko) | 2012-09-17 | 2021-01-15 | 세다르스-신나이 메디칼 센터 | 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료 |
EP3054977B1 (en) | 2013-10-09 | 2021-07-21 | Cedars-Sinai Medical Center | Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease |
RU2706361C2 (ru) | 2014-10-09 | 2019-11-18 | Седарс-Синаи Медикал Сентер | Способы и системы для отличия синдрома раздраженного кишечника от воспалительного заболевания кишечника и глютеновой болезни |
CN108913794B (zh) * | 2018-08-17 | 2023-08-22 | 河南省农业科学院畜牧兽医研究所 | 弯曲菌细胞膨胀致死毒素a型,b型和c型三重pcr检测引物及试剂盒 |
CN113655035B (zh) * | 2021-08-12 | 2024-06-28 | 深圳上泰生物工程有限公司 | 一种糖缺失性转铁蛋白分离方法及检测方法与试剂盒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10508499A (ja) * | 1994-11-14 | 1998-08-25 | アンスティテュ パストゥール | カンピロバクターのゲノム核酸配列と特異的にハイブリダイズするヌクレオチド配列 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0232085B1 (en) | 1986-01-22 | 1993-04-28 | Amoco Corporation | Campylobacter probe |
US5447848A (en) | 1986-01-22 | 1995-09-05 | Amoco Corporation | Detection of campylobacter with nucleic acid probes |
FR2633941A1 (fr) | 1988-07-05 | 1990-01-12 | Ire Medgenix Sa | Sondes d'acides nucleiques utiles pour detecter de maniere specifique differentes especes bacteriennes du genre campylobacter |
JPH03112498A (ja) | 1989-09-27 | 1991-05-14 | Shimadzu Corp | カンピロバクター検出のためのオリゴヌクレオチドおよびそれを用いた検出方法 |
JP3112498B2 (ja) | 1991-05-17 | 2000-11-27 | 日本ジーイープラスチックス株式会社 | ポリエステルカーボネートの製造方法 |
JPH0690795A (ja) | 1992-01-24 | 1994-04-05 | Toagosei Chem Ind Co Ltd | カンピロバクター ジェジュニ検出用プローブ及び検出方法 |
JPH0690796A (ja) | 1992-01-28 | 1994-04-05 | Toagosei Chem Ind Co Ltd | カンピロバクター ジェジュニ及びコリ検出用プローブ及び検出方法 |
JPH05276999A (ja) | 1992-04-02 | 1993-10-26 | Toyobo Co Ltd | カンピロバクター属細菌検出用オリゴヌクレオチド、カンピロバクター属細菌の検出法及び検出用試薬キット |
FR2701028B1 (fr) | 1993-01-29 | 1995-04-21 | Pasteur Institut | Séquences oligonucléotidiques hybridant spécifiquement avec une séquence génonique de campylobacter jejuni. Applications comme sondes et amorces oligonucléotidiques. |
JP2875632B2 (ja) | 1994-12-27 | 1999-03-31 | モトローラ・インコーポレーテッド | サイマルカスト無線通信システムにおいて送信機を識別するための方法および装置 |
CA2284844A1 (en) | 1997-03-25 | 1998-10-01 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health | A porin gene from campylobacter jejuni, related products and uses thereof |
US6066461A (en) | 1999-04-12 | 2000-05-23 | Becton Dickinson And Company | Amplification and detection of Campylobacter jejuni and Campylobacter coli |
IL149062A0 (en) * | 1999-10-12 | 2002-11-10 | Connex Ges Zur Optimierungvon | Improved method for detecting acid resistant microorganisms in the stool |
US7205104B2 (en) | 2000-03-24 | 2007-04-17 | Eppendorf Array Technologies Sa (Eat) | Identification of biological (micro) organisms by detection of their homologous nucleotide sequences on arrays |
US7595386B2 (en) * | 2003-01-24 | 2009-09-29 | William Beaumont Hospital | Methods and compositions for heat activated gene therapy using cytolethal distending toxin |
ES2456710T3 (es) | 2003-12-05 | 2014-04-23 | Fuso Pharmaceutical Industries Ltd. | Genes de toxinas de distensión citoletales como dianas para la detección de bacterias Campylobacter |
AU2008292946B2 (en) | 2007-08-24 | 2014-06-05 | Fuso Pharmaceutical Industries, Ltd. | Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin |
AU2008292375B8 (en) | 2007-08-31 | 2014-08-14 | Fuso Pharmaceutical Industries, Ltd. | Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin |
-
2004
- 2004-12-03 ES ES04819936.8T patent/ES2456710T3/es active Active
- 2004-12-03 CN CN201310328897.6A patent/CN103397041B/zh active Active
- 2004-12-03 KR KR1020117028508A patent/KR101202934B1/ko active IP Right Grant
- 2004-12-03 US US10/581,757 patent/US7563594B2/en active Active
- 2004-12-03 CA CA2903388A patent/CA2903388C/en active Active
- 2004-12-03 KR KR1020067013342A patent/KR101152078B1/ko active IP Right Grant
- 2004-12-03 EP EP04819936.8A patent/EP1698698B1/en active Active
- 2004-12-03 WO PCT/JP2004/018042 patent/WO2005054472A1/ja active Application Filing
- 2004-12-03 CA CA2548381A patent/CA2548381C/en active Active
- 2004-12-03 CN CN2004800412576A patent/CN1914322B/zh active Active
- 2004-12-03 JP JP2005515991A patent/JP4624927B2/ja active Active
- 2004-12-03 CN CN201210085750.4A patent/CN102634524B/zh active Active
- 2004-12-03 DK DK04819936.8T patent/DK1698698T3/da active
- 2004-12-03 PT PT48199368T patent/PT1698698E/pt unknown
- 2004-12-03 AU AU2004295596A patent/AU2004295596C1/en active Active
-
2009
- 2009-06-30 US US12/495,289 patent/US8168408B2/en active Active
- 2009-06-30 US US12/495,309 patent/US8343723B2/en active Active
-
2012
- 2012-04-27 US US13/458,532 patent/US8354500B2/en active Active
- 2012-10-31 HK HK12110930.8A patent/HK1170263A1/xx unknown
-
2014
- 2014-01-17 HK HK14100536.5A patent/HK1187642A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10508499A (ja) * | 1994-11-14 | 1998-08-25 | アンスティテュ パストゥール | カンピロバクターのゲノム核酸配列と特異的にハイブリダイズするヌクレオチド配列 |
Non-Patent Citations (5)
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168408B2 (en) | 2003-12-05 | 2012-05-01 | Fuso Pharmaceutical Industries, Ltd. | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
US8354500B2 (en) | 2003-12-05 | 2013-01-15 | Fuso Pharmaceutical Industries, Ltd. | Cytolethal distending toxins and detection of campylobacter bacteria using the same as a target |
US8343723B2 (en) | 2003-12-05 | 2013-01-01 | Fuso Pharmaceutical Industries, Ltd. | Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target |
JP2014027956A (ja) * | 2007-08-24 | 2014-02-13 | Osaka Prefecture Univ | 細胞膨張化致死毒を標的としたカンピロバクター属細菌の検出 |
JP2010130901A (ja) * | 2007-08-24 | 2010-06-17 | Osaka Prefecture Univ | 細胞膨張化致死毒を標的としたカンピロバクター属細菌の検出 |
US9200330B2 (en) | 2007-08-24 | 2015-12-01 | Osaka Prefecture University | Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin |
CN101835897A (zh) * | 2007-08-31 | 2010-09-15 | 公立大学法人大阪府立大学 | 靶向细胞致死肿胀毒素检测属于弯曲杆菌属的细菌 |
KR20100080595A (ko) | 2007-08-31 | 2010-07-09 | 고리츠다이가쿠호징 오사카후리츠다이가쿠 | 세포팽창화 치사독을 표적으로 한 캄필로박터속 세균의 검출 |
US8586327B2 (en) | 2007-08-31 | 2013-11-19 | Osaka Prefecture University | Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin |
JP5345936B2 (ja) * | 2007-08-31 | 2013-11-20 | 公立大学法人大阪府立大学 | 細胞膨張化致死毒を標的としたカンピロバクター属細菌の検出 |
WO2009028662A1 (ja) | 2007-08-31 | 2009-03-05 | Osaka Prefecture University | 細胞膨張化致死毒を標的としたカンピロバクター属細菌の検出 |
CN101835897B (zh) * | 2007-08-31 | 2014-05-14 | 公立大学法人大阪府立大学 | 通过靶向细胞致死肿胀毒素对弯曲杆菌属细菌进行的检测 |
US9663828B2 (en) | 2007-08-31 | 2017-05-30 | Osaka Prefecture University Public Corporation | Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin |
EP3255148A1 (en) | 2007-08-31 | 2017-12-13 | Osaka Prefecture University | Detection of bacterium belonging to the genus campylobacter which targets cytolethal distending toxin |
JP2016086754A (ja) * | 2014-11-06 | 2016-05-23 | Jnc株式会社 | カンピロバクター検出用培地 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8354500B2 (en) | Cytolethal distending toxins and detection of campylobacter bacteria using the same as a target | |
JP5770795B2 (ja) | 細胞膨張化致死毒を標的としたカンピロバクター属細菌の検出 | |
US9200330B2 (en) | Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005515991 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2548381 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004295596 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004819936 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004295596 Country of ref document: AU Date of ref document: 20041203 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067013342 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480041257.6 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004819936 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067013342 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10581757 Country of ref document: US Ref document number: 2007212691 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10581757 Country of ref document: US |